Net Cash Provided by (Used in) Financing Activities in USD of Nurix Therapeutics, Inc. from 2019 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Nurix Therapeutics, Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2019 to Q1 2025.
  • Nurix Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 28 Feb 2025 was $1,473,000, a 9.3% decline year-over-year.
  • Nurix Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $485,667,000, a 14997% increase from 2023.
  • Nurix Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $3,217,000, a 97% decline from 2022.
  • Nurix Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $117,192,000, a 24% decline from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Nurix Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $1,473,000 -$151,000 -9.3% 01 Dec 2024 28 Feb 2025 10-Q 08 Apr 2025 2025 Q1
Q1 2024 $1,624,000 +$143,000 +9.7% 01 Dec 2023 29 Feb 2024 10-Q 08 Apr 2025 2025 Q1
Q1 2023 $1,481,000 -$7,000 -0.47% 01 Dec 2022 28 Feb 2023 10-Q 10 Apr 2024 2024 Q1
Q1 2022 $1,488,000 +$129,000 +9.5% 01 Dec 2021 28 Feb 2022 10-Q 13 Apr 2023 2023 Q1
Q1 2021 $1,359,000 +$1,313,000 +2854% 01 Dec 2020 28 Feb 2021 10-Q 08 Apr 2022 2022 Q1
Q1 2020 $46,000 01 Dec 2019 29 Feb 2020 10-Q 13 Apr 2021 2021 Q1

Nurix Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $485,667,000 +$482,450,000 +14997% 01 Dec 2023 30 Nov 2024 10-K 28 Jan 2025 2024 FY
2023 $3,217,000 -$113,975,000 -97% 01 Dec 2022 30 Nov 2023 10-K 28 Jan 2025 2024 FY
2022 $117,192,000 -$36,690,000 -24% 01 Dec 2021 30 Nov 2022 10-K 28 Jan 2025 2024 FY
2021 $153,882,000 -$185,142,000 -55% 01 Dec 2020 30 Nov 2021 10-K 09 Feb 2023 2022 FY
2020 $339,024,000 +$338,898,000 +268967% 01 Dec 2019 30 Nov 2020 10-K 28 Jan 2022 2021 FY
2019 $126,000 01 Dec 2018 30 Nov 2019 10-K 28 Jan 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.